Newly diagnosed patients with multiple myeloma and severe renal impairment research hub

A Phase 2 Study of Isatuximab in combination with Bortezomib, Cyclophosphamide and Dexamethasone followed by isatuximab and lenalidomide maintenance in Newly Diagnosed Patients with Multiple Myeloma and severe Renal Impairment

This study looks at a new combination of medicines, including isatuximab, for people newly diagnosed with multiple myeloma and kidney problems. Researchers want to see how well these treatments help reduce kidney damage and slow down the myeloma.